Myanmar Health Sciences Research Journal

Download Citation



1.       Wang JC & Bennett M. Aging and Atherosclerosis. Circulation Research 2012; 111(2): 245-259.

2.       Acharjee S, Roe MT, Amsterdam EA, Holmes DN & Boden WE. Relation of admission high-density lipoprotein cho-lesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). American Journal of Cardiology 2013; 112(8):

3.       Lyons JG, O’Dea K & Walker KZ. Evidence for low high-density lipo-protein cholesterol levels in Australian indigenous peoples:
A systematic review. BMC Public Health 2014; 14: 545.

4.     Toth PP, Barter PJ, Rosenson RS, et al. High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology 2013; 7(5): 484-525.

5.     Chapman MJ, Crockett SC, Purvis PE, et al. Macrovascular disease in the elderly with type 1 diabetes. Journal of Diabetes & Metabolism 2013; 4(8): 299.

6.       Sunn HK. Lipoprotein (a) Level in Patients with Acute Myocardial Infarction in Myanmar. [MMedSc thesis]. University of Medicine 1: Yangon; 2003.

7.     Barter PJ, Brewer HB, Chapman MJ, Hennekens CH, Rader DJ & Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology 2003; 23(2): 160-167.

8.     Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M & Montalto G. Emerging therapies for raising high-density lipo-protein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Practice & Research Clinical Endocrinology & Meta-bolism 2014; 28(3): 453-461.

9.       Kingwell BA & Chapman MJ. Future
of high-density lipoprotein infusion therapies: Potential for clinical management of vascular disease. Circulation 2013; 128(10): 1112-1121.

10.    Superko HR, Pendyala L, Williams PT, Momary KM, King SB & Garrett BC.
High-density lipoprotein subclasses and
their relationship to cardiovascular disease. Journal of Clinical Lipidology 2012; 6(6): 496-523.

11.    Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clinical Chemistry 2011; 57(3): 392-410.

12.    Pirillo A, Norata GD & Catapano AL. High-density lipoprotein subfractions - what the clinicians need to know. Cardiology 2013; 124(2): 116-125.

13.    Johansson J, Carlson LA, Landou C & Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong in-verse relation with the largest particles is confined to normotriglyceridemic patients. Arteriosclerosis, Thrombosis 1991; 11(1): 174-182.

14.    Drexel H, Amann FW, Rentsch K, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary artery disease. American Journal of Cardiology 1992; 70(4): 436-440.

15.    Williams PT & Feldman DE. Prospective
study of coronary heart disease vs
HDL2, HDL3, and other lipoproteins
in Gofman’s Livermore Cohort. Athero-sclerosis 2011; 214(1): 196-202.

16.    Xu R-X, Li S, Li X-L, et al. High-density lipoprotein subfractions in relation with
the severity of coronary artery disease: A Gensini score assessment. Journal of Clinical Lipidology 2015; 9(1): 26-34.

17.    Xu R-X, Zhang Y, Ye P, et al. Analysis of lipoprotein subfractions in Chinese Han patients with stable coronary artery disease. Heart, Lung and Circulation 2015; 24(12): 1203-1210.

18.    Deurenberg P, Weststrate JA & Seidell JC. Body mass index as a measure of body fatness: Age- and sex-specific prediction formulas. British Journal of Nutrition 1991; 65(2): 105-114.

19.    Hirano T, Nohtomi K, Koba S, Muroi A & Ito Y. A simple and precise method for measuring HDL-cholesterol subfractions
by a single precipitation followed by homogenous HDL-cholesterol assay. Journal of Lipid Research 2008; 49(5): 1130-1136.

20.    Richmond W. Preparation and properties of a cholesterol oxidase from nocardia sp. and Its application to the enzymatic assay of total cholesterol in serum. Clinical Chemistry 1973; 19(12): 1350-1356.

21.    Trinder P. Determination of total cholesterol, high density lipoprotein cholesterol and triglycerids by enzymatic colourimetric method. Journal of Clinical Pathology 1969; 22: 158-162.

22.    McNamara JR, Cohn JS, Wilson PW & Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clinical Chemistry 1990; 36(1): 36-42.

23.    Smuts CM, Weich HF, Weight MJ, et al. Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk
indicator in patients with angiographically documented coronary artery disease. Coro-nary Artery Disease 1994; 5(4): 331-338.

24.    Kim DS, Burt AA, Rosenthal EA, et al. HDL3 is a superior predictor of carotid artery disease in a casecontrol cohort of 1725 participants. Journal of the American Heart Association 2014; 3(3).

25.    Maeda S, Nakanishi S, Yoneda M, et al. Associations between Small Dense LDL, HDL Subfractions (HDL2, HDL3) and Risk of Atherosclerosis in Japanese-Americans. Journal of Atherosclerosis and Thrombosis. 2012; 19(5): 444-452.

26.    Salonen JT, Salonen R, Seppänen K, Rauramaa R & Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of
acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84(1): 129-139.

27.    Tian L, Xu Y, Fu M, Peng T, Liu Y & Long S. The impact of plasma triglyceride and apolipoproteins concentrations on
high-density lipoprotein subclasses distri-bution. Lipids in Health and Disease 2011; 10: 17.

28.    Davidson MH, Ose L, Frohlich J, et al. Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clinical Cardiology 2003; 26(11): 509-514.

29.    Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and athero-sclerosis. The New England Journal of Medicine 2011; 364(2): 127-135.

30.   Kennedy MA, Barrera GC, Nakamura K, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metabolism 2005; 1(2): 121-131.

31.  Wang N, Silver DL, Costet P & Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. Journal of Biological Chemistry 2000; 275(42): 33053-33058.

32.   Bellanger N, Orsoni A, Julia Z, et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hyper cholesterolemia.  Arteriosclerosis, Thrombosis, and Vascular Biology 2011; 31(7): 1675-1681.

33.   Tall AR. Plasma high density lipoproteins. Metabolism and relationship to athero-genesis. Journal of Clinical Investigation 1990; 86(2): 379-384.

34.    Shuhei N, Söderlund S, Jauhiainen M & Taskinen MR. Effect of HDL composition and particle size on the resistance of HDL to the oxidation. Lipids Health Diseases 2010; 9: 104.

35.    Kontush A, Chantepie S & Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arteriosclerosis, Throm-bosis, and Vascular Biology 2003; 23(10): 1881-1888.

36.   Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction con-centration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. Journal of Lipid Research 2012; 53(3): 540-547.

Vision : Achieving a healthier nation through application of research findings          Mission Statement : To Develop and promote solutions to the major health problems of Myanmar